Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Signpath Pharma patents

List of Signpath Pharma patents

List of 3-V Biosciences patents

List of NIPPON CHEMICAL INDUSTRIAL CO . , LTD. patents

List of Supernus Pharmaceuticals, Inc. patents

Quantum software venture capital investors

List of companies in Investec's investment portfolio

Patents where

Current Assignee

Name

is

Signpath Pharma

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10258691 Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies	Patent 10258691 was granted and assigned to Signpath Pharma on April, 2019 by the United States Patent and Trademark Office.		Signpath Pharma		United States Patent and Trademark Office	10258691	April 16, 2019
	‌ US Patent 10357458 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current	Patent 10357458 was granted and assigned to Signpath Pharma on July, 2019 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10357458	July 23, 2019
	‌ US Patent 10238602 Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies	Patent 10238602 was granted and assigned to Signpath Pharma on March, 2019 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10238602	March 26, 2019
	‌ US Patent 10449193 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies	Patent 10449193 was granted and assigned to Signpath Pharma on October, 2019 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10449193	October 22, 2019
	‌ US Patent 10532045 Liposomal mitigation of drug-induced inhibition of the cardiac I	Patent 10532045 was granted and assigned to Signpath Pharma on January, 2020 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10532045	January 14, 2020
	‌ US Patent 9682041 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current	Patent 9682041 was granted and assigned to Signpath Pharma on June, 2017 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	9682041	June 20, 2017
	‌ US Patent 10117881 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies	Patent 10117881 was granted and assigned to Signpath Pharma on November, 2018 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10117881	November 6, 2018
	‌ US Patent 10975111 Cardiopathy-reducing phosphodiester lipids	Patent 10975111 was granted and assigned to Signpath Pharma on April, 2021 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10975111	April 13, 2021
	‌ US Patent 10617639 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current	Patent 10617639 was granted and assigned to Signpath Pharma on April, 2020 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10617639	April 14, 2020
	‌ US Patent 8753674 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current	Patent 8753674 was granted and assigned to Signpath Pharma on June, 2014 by the United States Patent and Trademark Office.		Signpath Pharma		United States Patent and Trademark Office	8753674	June 17, 2014
	‌ US Patent 10485768 Treatment for glioblastoma	Patent 10485768 was granted and assigned to Signpath Pharma on November, 2019 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	10485768	November 26, 2019
	‌ US Patent 9393198 Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders	Patent 9393198 was granted and assigned to Signpath Pharma on July, 2016 by the United States Patent and Trademark Office.		Signpath Pharma		United States Patent and Trademark Office	9393198	July 19, 2016
	‌ US Patent 11643424 Cardiopathy-reducing phosphodiester lipids	Patent 11643424 was granted and assigned to Signpath Pharma on May, 2023 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	11643424	May 9, 2023
	‌ US Patent 9170257 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin	Patent 9170257 was granted and assigned to Signpath Pharma on October, 2015 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	9170257	October 27, 2015
	‌ US Patent 8747890 Intravenous infusion of curcumin and a calcium channel blocker	Patent 8747890 was granted and assigned to Signpath Pharma on June, 2014 by the United States Patent and Trademark Office.		Signpath Pharma		United States Patent and Trademark Office	8747890	June 10, 2014
	‌ US Patent 12004868 Liposomal mitigation of drug-induced inhibition of the cardiac I	Patent 12004868 was granted and assigned to Signpath Pharma on June, 2024 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	12004868	June 11, 2024
	‌ US Patent 11746119 Cardiopathy-reducing phosphodiester lipids	Patent 11746119 was granted and assigned to Signpath Pharma on September, 2023 by the United States Patent and Trademark Office.	Signpath Pharma	Signpath Pharma		United States Patent and Trademark Office	11746119	September 5, 2023

17 results

0 selected

17 results

0 selected